Page 6 - Afmd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investors have begun to flirt with a sector that has been distinctly out of favor for more than two years.

Boone Capital Management LLC bought a new position in shares of Affimed (NASDAQ:AFMD – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,869,744 shares of the biopharmaceutical company’s stock, valued at approximately $3,558,000. Affimed makes up about 1.8% of […]

Affimed (NASDAQ:AFMD – Get Rating) had its price objective trimmed by HC Wainwright from $6.00 to $5.00 in a research note published on Monday morning, The Fly reports. A number of other brokerages have also issued reports on AFMD. StockNews.com began coverage on shares of Affimed in a research note on Thursday, May 18th. They […]

Affimed (NASDAQ:AFMD – Get Rating) – Equities researchers at HC Wainwright increased their Q2 2023 earnings estimates for Affimed in a research report issued on Wednesday, May 24th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.25). HC […]

Affimed (NASDAQ:AFMD – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […]